Clinical need: Temporal lobe epilepsy (TLE) is common, contributes to morbidity, and is frequently drug resistant. Current pharmacotherapy for acquired epilepsy is symptomatic, suppressing seizures but does not impact the development or progression of the disease. and neither the neurobehavioural commorbidities.
Significance: This study will determine if treatment with sodium selenate in chronically epileptic animals reverses the progression of epilepsy and mitigates the associated comorbidities. Moreover, this study will evaluate whether sodium selenate is able to reduce pharmacoresistance in an an animal model of established drug resistance TLE.
Sodium selenate would mitigate the severity and comorbidities of the epileptic condition and reduce pharmacoresistance in a model of established drug resistance TLE.
In model of established drug resistant TLE;
1. Treatment with sodium selenate will mitigate the number and severity of the seizures.
2. Sodium selenate treatment will reduce the neuropsychiatric comorbidities
3: To evaluate sodium selenate treatment will decrease resistance to standard anti-seizure AED treatment.
3. Sodium selenate would mitigate the structural changes and brain connectivity damage seen both microscopically and macroscopic levels.
Translation: This project could have major clinical implications, because it would be relevant to the majority of patients who present with chronic drug resistant acquired epilepsy. Importantly, sodium selenate has a favourable safety profile in early phase clinical trials facilitating the translation of the results of this preclinical study into a clinical trial of epilepsy disease modification